# Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery

> **NCT00667901** · PHASE1 · TERMINATED · sponsor: **University of Medicine and Dentistry of New Jersey** · enrollment: 15 (estimated)

## Conditions studied

- Melanoma (Skin)

## Interventions

- **DRUG:** riluzole
- **GENETIC:** protein expression analysis
- **GENETIC:** reverse transcriptase-polymerase chain reaction
- **GENETIC:** western blotting
- **OTHER:** immunohistochemistry staining method
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacological study
- **PROCEDURE:** neoadjuvant therapy
- **PROCEDURE:** therapeutic conventional surgery

## Key facts

- **NCT ID:** NCT00667901
- **Lead sponsor:** University of Medicine and Dentistry of New Jersey
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-02
- **Primary completion:** 2008-10
- **Final completion:** 2008-11
- **Target enrollment:** 15 (ESTIMATED)
- **Why stopped:** All enrollment, treatment, follow-up \& data analysis completed
- **Last updated:** 2009-12-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00667901

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00667901, "Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00667901. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*